ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 447 for:    "Juvenile myelomonocytic leukemia"

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02807272
Recruitment Status : Recruiting
First Posted : June 21, 2016
Last Update Posted : October 12, 2017
Sponsor:
Information provided by (Responsible Party):
Kura Oncology, Inc.

Brief Summary:
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 20 eligible subjects with CMML. Subjects will receive tipifarnib administered orally, twice a day (bid) for 7 days in alternating weeks (Days 1-7 and 15-21) in 28 day cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. If a complete response is observed, therapy with tipifarnib will be maintained for at least 6 months beyond the start of response.

Condition or disease Intervention/treatment Phase
Leukemia, Myelomonocytic, Chronic Drug: Tipifarnib Phase 2

Detailed Description:

This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in approximately 20 eligible subjects with CMML. This trial is planned as a single treatment trial with statistical comparison to historical ORR rate. The primary objective is to provide evidence that the TRUE underlying ORR in all subjects and/or in the KRAS/NRAS wild-type subgroup exceeds the historical rate. Only consented subjects who meet all eligibility criteria will be enrolled in the study. Eligible subjects will receive tipifarnib administered at a starting dose of 1200 mg or 900 mg, orally with food, bid for 7 days in alternating weeks (Days 1-7 and 15-21) in 28 day cycles. Stepwise 300 mg dose reductions to control treatment-related, treatment-emergent toxicities are allowed.

If a complete response is observed, therapy with tipifarnib will be maintained for at least 6 months beyond the start of response. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. Provisions will be made for the continuation of study treatment in subjects whose disease has not progressed beyond the end of the study, e.g. a single patient treatment protocol.

Determination of disease response will be performed by the Investigator according to the MDS/MPN IWG criteria. Similarly, disease progression will also be determined based on the MDS/MPN IWG criteria. Upon disease progression, all subjects will be followed approximately every 12 weeks for survival and the use of subsequent therapy until either death or 12 months after accrual of the study cohort has been completed, whichever occurs first. Information on survival and subsequent anticancer therapy may be collected by phone.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Study Start Date : October 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : April 2019


Arm Intervention/treatment
Experimental: Tipifarnib, Oral Drug: Tipifarnib
Oral tablet
Other Names:
  • R115777
  • Zarnestra




Primary Outcome Measures :
  1. Number of patients with CMML who obtain objective response following treatment with tipfarnib [ Time Frame: 1 year ]
  2. Number of patients with CMML whose disease is KRAS/NRAS wild type who obtain objective response following treatment with tipfarnib. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Rate of complete response (CR) [ Time Frame: 1 year ]
  2. Duration of Response [ Time Frame: 1 year ]
  3. Rate of progression free survival (PFS) [ Time Frame: 1 year ]
  4. Rate of survival [ Time Frame: 1 year ]
  5. Number of patients that experience Adverse Events (AEs) [ Time Frame: Until 30 days following end of study ]
  6. Rate of complete cytogenetic remission [ Time Frame: 1 year ]
  7. Rate of partial cytogenetic remission [ Time Frame: 1 year ]
  8. Rate of marrow response [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures (including bone marrow assessments).
  • At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 7. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.
  • Acceptable liver function:

    1. Total or direct bilirubin ≤ 2 times upper limit of normal (x ULN); does not apply to subjects with Gilbert's syndrome diagnosed as per institutional guidelines.
    2. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN.
  • Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.
  • Female subjects must be:

    1. Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); or
    2. If of child-bearing pIf of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for 2 weeks prior to screening, during, and at least 4 weeks after last dose of study medication. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of study medication.
    3. Not breast feeding at any time during the study.
  • Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria:

  • Known prior progression to acute myeloid leukemia (AML) defined by at least 20% blasts in the blood or bone marrow.
  • Myeloproliferative/myelodysplastic syndrome other than CMML. CMML with t(5;12) that have not yet received imatinib.
  • Participation in any interventional study within 4 weeks of randomization or 5 half-lives of the prior treatment agent (whichever is longer).
  • Ongoing treatment with an anticancer agent for CMML not contemplated in this protocol. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 7.
  • Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF).
  • Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor.
  • Active coronary artery disease requiring treatment, myocardial infarction within the prior year, New York Heart Association grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  • Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
  • Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
  • Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
  • The subject has legal incapacity or limited legal capacity.
  • Significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02807272


Contacts
Contact: Mary Traynor 617-588-3760 medicalaffairs@kuraoncology.com

Locations
United States, California
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute, Inc. Recruiting
Tampa, Florida, United States, 33612
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Weill Cornell Medicine Not yet recruiting
New York, New York, United States, 10065
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Kura Oncology, Inc.

Responsible Party: Kura Oncology, Inc.
ClinicalTrials.gov Identifier: NCT02807272     History of Changes
Other Study ID Numbers: KO-TIP-004
First Posted: June 21, 2016    Key Record Dates
Last Update Posted: October 12, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases
Tipifarnib
Antineoplastic Agents